Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | MIF | P14174 | 2/20 | 0.44 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.44 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18423283 | 1.00 | ELANE (0.46) | ELANEALDH1A1MAPTHPGDTHRB | |
| SCHEMBL6267768 | 0.82 | NDUFS8 (0.55) | ELANEALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL1501288 | 0.82 | POLB (0.45) | ALDH1A1MAPTHPGDGLAMIF | |
| SCHEMBL14693924 | 0.81 | MIF (0.47) | ALDH1A1MAPTGLAMIFMEN1 | |
| SCHEMBL4292455 | 0.78 | MIF (0.42) | ALDH1A1MAPTHPGDTHRBGLA | |
| Arachidonic Acid SCHEMBL28529406 | 0.77 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDTHRBGLA | |
| SCHEMBL28529405 | 0.76 | NDUFS8 (0.57) | ALDH1A1MAPTHPGDGLACNR1 | |
| SCHEMBL712741 | 0.76 | NDUFS8 (0.57) | ALDH1A1MAPTHPGDGLACNR1 | |
| SCHEMBL12081709 | 0.76 | NDUFS8 (0.57) | ALDH1A1MAPTHPGDGLACNR1 | |
| SCHEMBL27912643 | 0.75 | ELANE (0.52) | ELANEALDH1A1MAPTHPGDTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220106278-A1 | REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS | UNIVERSITY OF DELAWARE (US) | 2022-04-07 | — | — | US | disclosed |
| US-20210309669-A1 | Heterocyclic Spiro Compounds As MAGL Inhibitors | PFIZER INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3571202-B1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3823723-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | Pfizer Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3328849-B9 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | PFIZER INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3328849-B1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10626125-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10329308-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208607-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2018134695-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018134698-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-3328849-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | Pfizer Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9845301-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2017021805-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | ELANE 2560/4885ALDH1A1 471/4885MAPT 29/4885 |
| US-10626125-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | ELANE 3630/4885ALDH1A1 448/4885MAPT 21/4885 |
| US-20180208607-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | ELANE 3630/4885ALDH1A1 448/4885MAPT 21/4885 |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | TST, CYP4F8, CYP4Z1 | ELANE 2205/4885ALDH1A1 874/4885MAPT 1269/4885 |
| US-10329308-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | ELANE 3630/4885ALDH1A1 448/4885MAPT 21/4885 |
| US-20220106278-A1 | REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS | TST, CYP4F8, CYP4Z1 | ELANE 2205/4885ALDH1A1 874/4885MAPT 1269/4885 |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | ELANE 4701/4885ALDH1A1 408/4885MAPT 12/4885 |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | ELANE 2560/4885ALDH1A1 471/4885MAPT 29/4885 |
| US-20210309669-A1 | Heterocyclic Spiro Compounds As MAGL Inhibitors | MAG, ECH1, ECHS1 | ELANE 2606/4885ALDH1A1 135/4885MAPT 272/4885 |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | ELANE 2560/4885ALDH1A1 471/4885MAPT 29/4885 |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | MAG, MAGI3, APC | ELANE 4701/4885ALDH1A1 408/4885MAPT 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.